Imatinib-induced Severe Hepatitis in a 9-Year-old Girl With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Issue 6 (August 2015)

• Record Type: Journal Article
• Authors: Suzuki, Ryoko; Kobayashi, Chie; Sakai, Aiko; Fukushima, Hiroko; Tagawa, Manabu; Satomi, Kaishi; Nanmoku, Toru; Sumazaki, Ryo; Fukushima, Takashi
• Is Part Of: Journal of pediatric hematology/oncology. Volume 37:Issue 6(2015)
• Publication Date: 2015-08
• Subjects: Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000000337
• Languages: English
• ISSNs: 1077-4114

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <p>Imatinib mesylate has dramatically improved the outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL) and is now included as first-line therapy. Uncommon adverse effects of this drug for pediatric use, however, are largely unknown. We report the first case of a 9-year-old child who developed severe acute hepatitis with grade 4 transaminases and bilirubin elevation during imatinib treatment for Ph⁺ ALL. Liver biopsy showed extensive lobular and pericentral necrosis of hepatocytes. Liver function recovered after discontinuing imatinib with a 4-week prednisolone. Extensive hepatic necrosis should be considered not only in adults but also in children under imatinib administration.</p> </sec> </abstract>